Research2 sources
Triple-Target Incretin Drug Kills Knee Osteoarthritis Pain in Obesity
The Brief · written from 2 sources
- Two Northwestern University-led Phase III trials involving more than 1,000 participants tested an experimental weight-loss drug in people with painful knee osteoarthritis who are overweight or have obesity.
- MedPage Today reports that the investigational drug retatrutide was highly effective in reducing pain and improving disability in obesity-associated knee OA in the TRIUMPH-4 trial.
- The results were presented at a meeting in Orlando, according to MedPage Today's meeting coverage.
Why it matters
Knee osteoarthritis is treated mainly for pain and function, and this research suggests that weight-loss drugs may also ease symptoms in patients with obesity. The drug is still investigational, so its availability and safety profile remain open questions.
Who’s affected
- Adults with painful knee osteoarthritis who are overweight or have obesity
- Clinicians who manage osteoarthritis and obesity
- #osteoarthritis
- #obesity
- #weight-loss drugs
- #clinical trials
- #pain management
(MedPage Today) -- ORLANDO -- The investigational obesity drug retatrutide was highly effective in reducing pain and improving disability in knee osteoarthritis (OA) associated with obesity, according to the TRIUMPH-4 trial. Among patients in...
Timeline
Results of TRIUMPH-4 reported at a meeting in Orlando
Medical Xpress - latest medical and health news stories
Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials
MedPageToday.com - medical news for physicians
Triple-Target Incretin Drug Kills Knee Osteoarthritis Pain in Obesity
Full coverage · 2 sources
- 3h ago ↗
MedPageToday.com - medical news for physicians
Triple-Target Incretin Drug Kills Knee Osteoarthritis Pain in Obesity
- 8h ago ↗
Medical Xpress - latest medical and health news stories
Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials